Literature DB >> 26657740

Ischemic Heart Disease in Patients with End-Stage Kidney Disease.

Yuri Tanaka1, Nobuhiko Joki, Hiroki Hase.   

Abstract

BACKGROUND: It was recently reported that the severity of coronary and carotid atherosclerosis in patients with end-stage kidney disease (ESKD) has improved over the last two decades. However, the frequency of coronary artery events observed at the initiation of dialysis remains high.
SUMMARY: Recently, 5 different clinical types of acute myocardial infarction (MI) were introduced in the third universal definition of MI. Type 2 MI, known as secondary MI, is a more heterogeneous entity, where a condition other than coronary artery narrowing contributes to an acute imbalance in oxygen supply and demand. In patients with chronic kidney disease, it has been demonstrated that type 2 MI is more common than type 1 MI, which is associated with coronary occlusive disease. It is suspected that patients with ESKD also often have type 2 MI. Factors associated with incremental increases in oxygen demand may cause myocardial ischemia in ESKD. KEY MESSAGES: Significant epicardial coronary narrowing might not be a necessary precursor of myocardial ischemia in ESKD. To prevent ischemic heart disease and improve prognosis in patients with ESKD, we need to pay attention not only to coronary stenotic lesions, but also to the factors associated with the induction of an imbalance in myocardial oxygen supply and demand.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26657740     DOI: 10.1159/000441582

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  1 in total

1.  Diminishing dry weight is strongly associated with all-cause mortality among long-term maintenance prevalent dialysis patients.

Authors:  Yuji Sato; Tatsunori Toida; Hideto Nakagawa; Takashi Iwakiri; Ryuzoh Nishizono; Masao Kikuchi; Shouichi Fujimoto
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.